A Study to Demonstrate Immunogenicity and Tolerability of Gardasil (V501) Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Preadolescents, and To Determine End-Expiry Specifications for the Vaccine.

Trial Profile

A Study to Demonstrate Immunogenicity and Tolerability of Gardasil (V501) Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Preadolescents, and To Determine End-Expiry Specifications for the Vaccine.

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2014

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary) ; Human papillomavirus vaccine
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 16 Mar 2010 Actual patient number (3055) added as reported by ClinicalTrials.gov.
    • 14 Apr 2009 Trial phase changed from II/III to III as reported by ClinicalTrials.gov.
    • 18 Feb 2009 Actual end date added, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top